Subsequent Events [Abstract]
Subsequent Event [Table]
Subsequent Event [Table]
Collaborative Arrangements and Non-collaborative Arrangements [Axis]
Type of Arrangement and Non-arrangement Transactions [Axis]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]
Arrangements and Non-arrangement Transactions [Domain]
Sangamo BioSciences
Sangamo BioSciences [Member]
Sangamo BioSciences [Member]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Research and development expense
Research and Development Expense
Additional Milestone Payment
Additional Milestone Payment
Additional milestone payment.
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]
Award Type [Axis]
Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]
Equity Award [Domain]
Market stock units
Market Stock Units [Member]
Market stock units.
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market stock units activity
Market Stock Units Activity [Abstract]
Market stock units activity.
Beginning Balance, Unvested, Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Beginning Balance, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Shares, Granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Weighted Average Grant Date Fair Value, Granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Shares, Vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Weighted Average Grant Date Fair Value, Vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Shares, Forfeited
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Weighted Average Grant Date Fair Value, Forfeited
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Ending Balance, Unvested, Shares
Ending Balance, Weighted Average Grant Date Fair Value
Equity [Abstract]
Equity (Textual)
Equity (Textual) [Abstract]
Equity.
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Common stock shares authorized for repurchase
Stock Repurchase Program, Number of Shares Authorized to be Repurchased
Repurchase of common stock, shares
Treasury Stock, Shares, Acquired
Repurchase of common stock, value
Payments for Repurchase of Common Stock
Investments in Variable Interest Entities [Abstract]
Investments In Variable Interest Entities.
Investments in Variable Interest Entities
Investments In Variable Interest Entities [Text Block]
The entire disclosure for Variable Interest Entities (VIE). VIEs are interest in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.
Litigation [Abstract]
Litigation.
Loss Contingencies [Table]
Loss Contingencies [Table]
Genentech
Genentech [Member]
Genentech.
Products and Services [Axis]
Products and Services [Axis]
Products and Services [Domain]
Products and Services [Domain]
RITUXAN
RITUXAN [Member]
RITUXAN.
Geographical [Axis]
Geographical [Axis]
Segment, Geographical [Domain]
Geographical [Domain]
ITALY
ITALY
Loss Contingencies by Nature of Contingency [Axis]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Hoechst
Hoechst [Member]
Hoechst [Member]
Canada Lease Dispute
Canada Lease Dispute [Member]
Canada lease dispute.
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Compensatory damages
Loss Contingency, Damages Sought, Value
Prejudgment interest
Prejudgment interest
Prejudgment interest
Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages
Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages
Decrease in share of co-promotion profits due to estimated compensation damages.
Payment in case of any unfavorable determination received
Loss Contingency, Estimate of Possible Loss
Limited period for government reimbursement
Limited Period For Government Reimbursement
Limited period for government reimbursement.
Automatic renewal period for the resolution
Automatic Renewal Period For Resolution
Automatic renewal period for the resolution.
Reimbursement limit stated in the resolution
Reimbursement Limit Stated In Resolution
Reimbursement limit stated in the resolution.
Loss contingency, expected settlement
Loss contingency, expected settlement
Loss contingency, expected settlement
Reserves for Discounts and Allowances [Abstract]
Revenue reserves.
Revenue reserves reclassification
Revenue reserves reclassification
Revenue reserves reclassification from discounts to contractual adjustments
Summary of total product revenue reserves included in consolidated balance sheets
Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Abstract]
Summary of product revenue reserves included in consolidated balance sheets.
Reduction of accounts receivable
Product Revenue Reserves Classified As Reduction Of Accounts Receivable
Product revenue reserves classified as a reduction of accounts receivable.
Components of accrued expenses
Product Revenue Reserves Classified As Reduction Of Current Liabilities
Product revenue reserves classified as a reduction of current liabilities.
Total reserves
Product Revenue Reserves
Period balance related to product revenue reserves.
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table]
Schedule of Finite-Lived Intangible Assets [Table]
Business Acquisition [Axis]
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree [Domain]
Stromedix
Stromedix [Member]
Stromedix.
TYSABRI product
TYSABRI product [Member]
TYSABRI product [Member]
AVONEX
AVONEX [Member]
AVONEX
Indefinite-lived Intangible Assets by Major Class [Axis]
Indefinite-lived Intangible Assets [Axis]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
Indefinite-lived Intangible Assets, Major Class Name [Domain]
In-process research and development
In Process Research and Development [Member]
Trademarks and trade names
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name [Domain]
Out-licensed patents
Out Licensed Patents [Member]
Out-licensed patents.
AVONEX developed technology
Developed Technology Rights [Member]
Acquired and in-licensed rights and patents
In Licensed Patents [Member]
In-licensed patents.
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets [Line Items]
Intangible assets
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Estimated life, (In Years)
Finite-Lived Intangible Asset, Useful Life
Indefinite lived intangible assets useful life
Indefinite Lived Intangible Assets Useful Life
Indefinite lived intangible assets useful life.
Cost
Finite-Lived Intangible Assets, Gross
Cost and net
Indefinite-Lived Intangible Assets (Excluding Goodwill)
Total intangible assets, gross
Intangible Assets, Gross (Excluding Goodwill)
Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Net
Finite-Lived Intangible Assets, Net
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Intangible Assets and Goodwill (Additional Textual)
Intangible Assets And Goodwill (Additional Textual) [Abstract]
Intangible assets and goodwill additional.
Expected future amortization expense, 2014
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
Expected future amortization expense, 2015
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Expected future amortization expense, 2016
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Expected future amortization expense, 2017
Finite-Lived Intangible Assets, Amortization Expense, Year Four
Expected future amortization expense, 2018
Finite-Lived Intangible Assets, Amortization Expense, Year Five
FiniteLivedIntangibleAssetsFutureAmortization
FiniteLivedIntangibleAssetsFutureAmortization
FiniteLivedIntangibleAssetsFutureAmortization
Amortization of acquired intangible assets
Amortization of Intangible Assets
Impairment of intangible asset
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Total purchase price allocated to IPR&D
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets
Net intangible asset
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles
Share-based compensation expense included in consolidated statements of income
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Summary of share-based compensation expense associated with each of our share-based compensating programs
Summary of Share Based Compensation Expense Associated With Different Programs [Table Text Block]
Summary of share based compensation expense associated with different programs.
Stock option activity
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Tax benefit and cash received from stock option exercises
Schedule of Cash Proceeds Received from Share-based Payment Awards [Table Text Block]
Market stock units activity
Schedule Of Market Stock Units Activity [Table Text Block]
Schedule Of Market Stock Units Activity.
Assumptions used in valuation of market based stock units
Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]
Assumptions used in valuation of market based stock units.
Cash settled performance shares activity
Schedule Of Cash Settled Performance Shares Activity [Table Text Block]
Schedule Of Cash Settled Performance Shares Activity.
Time-vested restricted stock units activity
Time Vested Restricted Stock Units Activity [Table Text Block]
Time Vested Restricted Stock Units Activity.
Performance-vested restricted stock units activity
Performance Vested Restricted Stock Units Activity [Table Text Block]
Performance Vested Restricted Stock Units Activity.
Shares issued under employee stock purchase plan
Shares Issued Under Employee Stock Purchase Plan [Table Text Block]
Shares issued under employee stock purchase plan.
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]
Derivative Instruments, Gain (Loss) [Table]
Derivative Instrument Risk [Axis]
Derivative Instrument [Axis]
Derivative Contract Type [Domain]
Derivative Contract [Domain]
Foreign Exchange Contract
Foreign Exchange Contract [Member]
Income Statement Location [Axis]
Income Statement Location [Axis]
Income Statement Location [Domain]
Income Statement Location [Domain]
Revenue
Sales [Member]
Other income (expense)
Other Income Expense [Member]
Other income (expense).
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) [Line Items]
Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]
Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net
Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness
Derivative, Net Hedge Ineffectiveness Gain (Loss)
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Plan Name [Axis]
Plan Name [Axis]
Plan Name [Domain]
Plan Name [Domain]
Stock options
Employee Stock Option [Member]
Time-vested restricted stock units
Time Vested Restricted Stock Units [Member]
Time vested restricted stock units.
Performance-vested restricted stock units settled in shares [Member]
Performance Vested Restricted Stock Units Settled In Shares [Member]
Performance vested restricted stock units settled in shares.
Cash settled performance shares
Cash settled performance shares [Member]
Cash settled performance shares [Member]
Employee stock purchase plan
Employee Stock Purchase Plan [Member]
Employee stock purchase plan.
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Summary of share based compensation expense associated with different programs
Summary of share based compensation expense associated with different programs [Abstract]
Summary of share-based compensation expense associated with different programs.
Share-based compensation expense
Allocated Share-based Compensation Expense
Subtotal
Allocated Share Based Compensation Expense Net
Allocated share based compensation expense net.
Capitalized share-based compensation costs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount
Share-based compensation expense included in total costs and expenses
Share Based Compensation Expense Included In Costs And Expenses
Share based compensation expense included in costs and expenses.
Investments, All Other Investments [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Business Acquisitions, by Acquisition [Table]
Portola Pharmaceuticals Member
Portola Pharmaceuticals Member
Portola pharmaceuticals.
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Major Types of Debt and Equity Securities [Domain]
Strategic Investments
Strategic Investments [Member]
Strategic investments.
Stromedix, Inc.
Business Acquisition
Business Acquisition [Line Items]
Strategic investment portfolio
Strategic Investment Portfolio
Strategic investment portfolio.
Venture capital investments
Venture Capital Investments
Venture capital investments.
Cost basis of equity securities of certain privately-held companies and venture capital funds
Cost Method Investments
Net gains (losses) realized
Realized Investment Gains (Losses)
Recognized gain
Gain Loss Recognized During Acquisition Relating To Pre Existing Equity Interest
Gain/loss recognized during acquisition relating to pre-existing equity interest.
Number of strategic investments sold
Number Of Strategic Investments Sold
Number of strategic investments sold.
Selling price of strategic investments
Selling Price Of Strategic Investments
Selling Price Of Strategic Investments
Gain (loss) from sale of strategic equity investments
Gain Loss From Sale Of Strategic Equity Investments
Gain (loss) from sale of strategic equity investments.
Intangible Assets and Goodwill
Goodwill and Intangible Assets Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments and Contingencies Disclosure [Abstract]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]
Minimum [Member]
Maximum
Prior twelve month sales [Axis]
Prior twelve month sales [Axis]
Prior twelve month sales [Axis]
Prior twelve month sales [Domain]
Prior twelve month sales [Domain]
[Domain] for Prior twelve month sales [Axis]
Less than five hundred million [Member]
Less than five hundred million [Member]
Less than five hundred million [Member]
Five hundred million to one billion [Member]
Five hundred million to one billion [Member]
Five hundred million to one billion [Member]
One billion to one point five billion [Member]
One billion to one point five billion [Member]
One billion to one point five billion [Member]
One point five billion to two billion [Member]
One point five billion to two billion [Member]
One point five billion to two billion [Member]
Two billion to two point five billion [Member]
Two billion to two point five billion [Member]
Two billion to two point five billion [Member]
Two point five billion to three billion [Member]
Two point five billion to three billion [Member]
Two point five billion to three billion [Member]
Greater than three billion [Member]
Greater than three billion [Member]
Greater than three billion [Member]
Fumapharm AG
Fumapharm AG [Member]
Fumapharm AG [Member]
Cumulative sales level [Axis]
Cumulative sales level [Axis]
Cumulative sales level [Axis]
Cumulative sales level [Domain]
Cumulative sales level [Domain]
[Domain] for Cumulative sales level [Axis]
Five hundred million [Member]
Five hundred million [Member]
Five hundred million [Member]
One billion
One billion [Member]
One billion [Member]
Two billion [Member]
Two billion [Member]
Two billion [Member]
Three billion [Member]
Three billion [Member]
Three billion [Member]
Each additional one billion up to twenty billion [Member]
Each additional one billion up to twenty billion [Member]
Each additional one billion up to twenty billion [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Contingent Consideration [Line Items]
Sales level
Sales level
Sales level
Milestone payment due on the prior 12 month sales
Milestone payment due on the prior 12 month sales
Milestone payment due on the prior 12 month sales
Cumulative sales level
Cumulative sales level
Cumulative sales level
Each additional sales level
Each additional sales level
Each additional sales level
Quarterly Financial Information Disclosure [Abstract]
Schedule Of Development Milestone And Collaboration [Table]
Schedule Of Development Milestone And Collaboration [Table]
Schedule of development milestone and collaboration.
ISIS Pharmaceuticals
Isis Pharmaceuticals [Member]
Isis Pharmaceuticals [Member]
Schedule Of Development Milestone And Collaboration [Line Items]
Schedule Of Development Milestone And Collaboration [Line Items]
Schedule Of Development Milestone And Collaboration.
Decrease in share of co-promotion profits due to estimated compensation damages
Research and development
Tax accounting correction
Tax accounting correction
Tax accounting correction
Statement of Financial Position [Abstract]
ASSETS
Assets [Abstract]
Current assets:
Assets, Current [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Marketable securities
Available-for-sale Securities, Current
Accounts receivable, net
Accounts Receivable, Net, Current
Due from unconsolidated joint business, net
Due from unconsolidated joint business
Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.
Inventory
Inventory, Net
Other current assets
Other Assets, Current
Total current assets
Assets, Current
Marketable securities
Available-for-sale Securities, Noncurrent
Property, plant and equipment, net
Property, Plant and Equipment, Net
Intangible assets, net
Goodwill
Goodwill
Investments and other assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND EQUITY
Liabilities and Equity [Abstract]
Current liabilities:
Liabilities, Current [Abstract]
Current portion of notes payable and line of credit
Debt, Current
Taxes payable
Taxes Payable, Current
Accounts payable
Accounts Payable, Current
Accrued expenses and other
Other Liabilities, Current
Total current liabilities
Liabilities, Current
Notes payable and other financing arrangements
Long-term Debt
Long-term deferred tax liability
Deferred Tax Liabilities, Net, Noncurrent
Other long-term liabilities
Other Liabilities, Noncurrent
Total liabilities
Liabilities
Commitments and contingencies
Commitments and Contingencies
Equity:
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Biogen Idec Inc. shareholders' equity
Stockholders' Equity Attributable to Parent [Abstract]
Preferred stock, par value $0.001 per share
Preferred Stock, Value, Issued
Common stock, par value $0.0005 per share
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Retained earnings
Retained Earnings (Accumulated Deficit)
Treasury stock, at cost; 19,641 shares and 17,655 shares, respectively
Treasury Stock, Value
Total Biogen Idec Inc. shareholders’ equity
Stockholders' Equity Attributable to Parent
Noncontrolling interests
Stockholders' Equity Attributable to Noncontrolling Interest
Total equity
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Total liabilities and equity
Liabilities and Equity
Fair Value Disclosures [Abstract]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Document and Entity Information [Abstract]
Document and Entity Information.
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Public Float
Entity Public Float
Schedule of Stock by Class [Table]
Schedule of Stock by Class [Table]
Class of Stock [Axis]
Class of Stock [Axis]
Class of Stock [Domain]
Class of Stock [Domain]
Series A
Series A Preferred Stock [Member]
Series X Junior Participating
Series X Preferred Stock [Member]
Series X preferred stock.
Undesignated
Undesignated Preferred Stock [Member]
Undesignated preferred stock.
Class of Stock
Class of Stock [Line Items]
Summary of preferred stock
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Summary of common stock
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized
Common Stock, Shares Authorized
Common stock, shares issued
Common Stock, Shares, Issued
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Valuation and Qualifying Accounts Disclosure [Table]
Valuation and Qualifying Accounts Disclosure [Table]
Valuation Allowances and Reserves Type [Axis]
Valuation Allowances and Reserves Type [Axis]
Valuation Allowances and Reserves [Domain]
Valuation Allowances and Reserves [Domain]
Discounts
Reserve for Cash Discount [Member]
Contractual Adjustments
Contractual Adjustments [Member]
Contractual adjustments.
Returns
Sales Returns and Allowances [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation and Qualifying Accounts Disclosure [Line Items]
Analysis of the amount of, and change in, reserves
Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]
Analysis of the amount of, and change in product revenue reserves.
Beginning balance
Current provisions relating to sales in current year
Current Provisions To Product Revenue Reserves Relating To Sales In Current Year
Current provisions to product revenue reserves relating to sales in current year.
Adjustments relating to prior years
Adjustments To Product Revenue Reserves Relating To Sales In Prior Years
Adjustments to product revenue reserves relating to sales in prior years.
Payments/returns relating to sales in current year
Payments Returns Applied Against Product Revenue Reserves Relating To Current Year
Payments/ returns applied against product revenue reserves relating to current year.
Payments/returns relating to sales in prior years
Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year
Payments/ returns applied against product revenue reserves relating to prior year.
Ending balance
Vesting [Axis]
Vesting [Axis]
Vesting [Domain]
Vesting [Domain]
Annual Vesting
Annual Vesting [Member]
Annual Vesting [Member]
Title of Individual [Axis]
Title of Individual [Axis]
Title of Individual with Relationship to Entity [Domain]
Relationship to Entity [Domain]
Director
Director [Member]
Share Based Compensation Plan [Axis]
Share Based Compensation Plan [Axis]
Share based compensation plan.
Share Based Compensation Plan [Domain]
Share Based Compensation Plan [Domain]
Share based compensation plan.
Directors Plan
Directors Plan [Member]
Directors plan.
Omnibus Plans
Omnibus Plans [Member]
Omnibus plans.
Attainment Of Performance Criteria
Attainment Of Performance Criteria [Member]
Attainment of performance criteria.
Attainment Of Performance Criteria in 2010 [Member]
Attainment Of Performance Criteria in 2010 [Member]
Attainment Of Performance Criteria in 2010 [Member]
Performance vested restricted stock units
Performance Vested Restricted Stock Units [Member]
Performance vested restricted stock units.
Total number of shares of common stock for issuance
Number Of Shares Of Common Stock For Issuance
Total number of shares of common stock for issuance.
Ratio of total number of shares reserved under the plan
Ratio Of Number Of Shares Reserved Under Plan
Ratio of total number of shares reserved under the plan.
Number of equal annual increments
Number Of Equal Annual Increments
Number of equal annual increments.
Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)
Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent
Minimum target number of market stock units granted based on stock performance in percent.
Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)
Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent
Maximum target number of market stock units granted based on stock performance in percent.
Number of shares granted
Number of days for calculation of average closing stock price
Number Of Days For Calculation Of Average Closing Stock Price
Number of days for calculation of average closing stock price.
Cash in settlement of CSPS awards upon vesting
Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards
Time vested RSU vesting percentage
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage
Weighted average grant date fair value
Maximum percentage of earnings of target number of shares granted if maximum threshold limit is attained
Maximum Percentage Of Earnings Of Target Number Of Shares Granted If Maximum Threshold Limit Is Attained
Maximum percentage of earnings of target number of shares granted if maximum threshold limit is attained.
Share-Based Payments (Textual)
Share-Based Payments (Textual) [Abstract]
Share Based Payments.
Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation
Windfall Tax Benefits From Vesting Of Stock Awards Exercises Of Stock Options And ESPP Participation
Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation.
Unrecognized compensation cost related to unvested share-based compensation
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Weighted-average period to recognize the cost of unvested awards
Weighted Average Period To Recognize Cost Of Nonvested Awards
Weighted-average period to recognize the cost of nonvested awards.
Number of share-based compensation plans pursuant to which awards are currently being made
Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made
Number of share-based compensation plans pursuant to which awards are currently being made.
Number of share-based compensation plans pursuant to which no further awards will be made
Number Of Share Based Compensation Plans Pursuant To Which No Further Awards Will Be Made
Number of share-based compensation plans pursuant to which no further awards will be made.
Number of shares granted under stock options
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Total intrinsic value of options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Aggregate intrinsic values of options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Weighted average remaining contractual term for options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Outstanding stock options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Weighted-average exercise price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Aggregate intrinsic value of options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Weighted average remaining contractual term for options exercisable
Share Based Compensation Arrangements By Share Based Payment Award Options Exercisable Weighted Average Remaining Contractual Term
Share-based compensation arrangements by share-based payment award options exercisable weighted average remaining contractual term.
Total of vested and expected to vest options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Weighted average exercise price for vested and expected to vest options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Aggregate intrinsic value of vested and expected to vest options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Weighted average remaining contractual term of vested and expected to vest options
Share Based Compensation Arrangements By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
Share-based compensation arrangements by share-based payment award options vested and expected to vest outstanding weighted average remaining contractual term.
Gain on Sale of Rights [Abstract]
Gain on Sale of Rights [Abstract]
Gain on sale of rights
Gain on sale of rights
Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.
Marketable securities including strategic investments
Available-for-sale Securities [Table Text Block]
Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents
Schedule of Cash and Cash Equivalents [Table Text Block]
Summary of contractual maturities: Available-for-sale securities
Investments Classified by Contractual Maturity Date [Table Text Block]
Proceeds from marketable securities, excluding strategic investments
Proceeds From Marketable Debt Securities [Table Text Block]
Proceeds from marketable debt securities.
Business Combinations [Abstract]
STX One Hundred
STX One Hundred [Member]
STX one hundred.
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH
Corporate Joint Venture Investments Member
Corporate Joint Venture Investments.
Biogen Idec Hemophilia
Biogen Idec Hemophilia [Member]
Biogen Idec Hemophilia.
Acquisition of TYSABRI rights
Payments to Acquire Intangible Assets
Deferred revenue
Deferred Revenue, Current
Future contingent payment for the first 12 months
Future contingent payment for the first 12 months
Future contingent payment for the first 12 months
Future contingent payment for annual worldwide net sales up to $2.0 billion
Future contingent payment for annual worldwide net sales up to $2.0 billion
Future contingent payment for annual worldwide net sales up to $2.0 billion
Future contingent payment threshold
Future contingent payment threshold
Future contingent payment threshold
Future contingent payment for annual worldwide net sales that exceed $2.0 billion
Future contingent payment for annual worldwide net sales that exceed $2.0 billion
Future contingent payment for annual worldwide net sales that exceed $2.0 billion
Cash portion of consideration
Payments to Acquire Businesses, Gross
Maximum contingent consideration in the form of development and approval milestones
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Contingent consideration obligation
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Total purchase price allocated to goodwill
Discount rate used to calculate fair value of in process research and development
Fair Value In Process Research And Development Discount Rate
Discount rate used to calculate fair value of in process research and development.
Other goodwill adjustments
Other Goodwill Adjustments
Other Goodwill Adjustments
Percentage of equity interest to the portion of total capital stock
Equity Method Investment, Ownership Percentage
Recognized gain
Milestone payments made during period
Milestone Payments Made During Period
Milestone Payments Made During Period.
Additional contingent payment for Biologic license
Business Acquisition Cost Of Acquired Entity Additional Contingent Consideration Associated With Approval Of License Application
Business acquisition cost of acquired entity additional contingent consideration associated with approval of license application.
Additional contingent payment for marketing authorization
Business Acquisition Cost Of Acquired Entity Additional Contingent Consideration Associated With Grant Of Marketing Authorization
Business acquisition cost of acquired entity additional contingent consideration associated with grant of marketing authorization.
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Financial Information [Abstract]
Product, net
Sales Revenue, Goods, Net
Unconsolidated joint business revenues
Unconsolidated Joint Business
Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.
Other
Other Revenue, Net
Total revenues
Revenues
Gross Profit
Gross Profit
Net income
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net income attributable to Biogen Idec Inc
Net Income (Loss) Attributable to Parent
Basic earnings per share attributable to Biogen Idec Inc.
Earnings Per Share, Basic
Diluted earnings per share attributable to Biogen Idec Inc.
Earnings Per Share, Diluted
Statement of Stockholders' Equity [Abstract]
Statement [Table]
Statement [Table]
Statement, Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Total Biogen Idec Inc. shareholders' equity
Parent Company [Member]
Preferred stock
Preferred Stock [Member]
Common stock
Common Stock [Member]
Additional paid-in capital
Additional Paid-in Capital [Member]
Accumulated other comprehensive income (loss)
Accumulated Other Comprehensive Income (Loss) [Member]
Retained earnings
Retained Earnings [Member]
Treasury stock
Treasury Stock [Member]
Noncontrolling interests
Noncontrolling Interest [Member]
Statement [Line Items]
Statement [Line Items]
Beginning Balance
Beginning Balance, shares
Shares, Issued
Other comprehensive income, net of tax
Other Comprehensive Income (Loss), Net of Tax
Distributions to noncontrolling interests
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders
Capital contribution from noncontrolling interests
Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Deconsolidation of noncontrolling interests
Noncontrolling Interest, Decrease from Deconsolidation
Repurchase of common stock for Treasury pursuant to the 2011 share repurchase plan, at cost
Treasury Stock, Value, Acquired, Cost Method
Repurchase of common stock for Treasury pursuant to the 2011 stock repurchase plan, at cost, shares
Retirement Of Common Stock
Retirement Of Common Stock
Retirement of common stock.
Retirement Of Common Stock Shares
Retirement Of Common Stock Shares
Retirement of common stock shares.
Issuance of common stock under stock option and stock purchase plans
Stock Issued During Period, Value, Treasury Stock Reissued
Issuance of common stock under stock option and stock purchase plans, shares
Stock Issued During Period, Shares, Treasury Stock Reissued
Issuance of common stock under stock award plan
Stock Issued During Period, Value, Stock Options Exercised
Issuance of common stock under stock award plan, shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Compensation expense related to share-based payments
Tax benefit from share-based payments
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Acquisitions of noncontrolling interests
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests
Conversion of preferred stock
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures
Conversion of preferred stock, shares
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures
Recharacterization of share-based awards from equity to cash-settled due to restructuring
Adjustments To Additional Paid In Capital Due To Modified Restructuring Awards Settling In Cash
Adjustments to additional paid in capital due to modified restructuring awards settling in cash.
Ending Balance
Ending Balance, shares
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans
Pension and Other Postretirement Benefits Disclosure [Text Block]
Income before income tax provision and the income tax expense
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Components of deferred tax assets and liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Reconciliation between the U.S. federal statutory tax rate and effective tax rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Reconciliation of beginning and ending amount of unrecognized tax benefits
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Schedule of Goodwill [Table]
Schedule of Goodwill [Table]
TECFIDERA
TECFIDERA [Member]
TECFIDERA [Member]
Goodwill [Line Items]
Goodwill [Line Items]
Income tax expense
Income Tax Expense (Benefit)
Accumulated impairment losses related to goodwill
Goodwill, Impaired, Accumulated Impairment Loss
Summary of roll forward of the changes in goodwill
Goodwill [Roll Forward]
Goodwill, beginning of period
Increase to goodwill
Goodwill, Acquired During Period
Goodwill, end of period
Schedule of Cash and Cash Equivalents [Table]
Schedule of Cash and Cash Equivalents [Table]
Investment Type [Axis]
Investment Type [Axis]
Investment Type Categorization [Domain]
Investments [Domain]
Commercial Paper
Commercial Paper [Member]
Overnight Reverse Repurchase Agreements
Repurchase Agreements [Member]
Short-term Debt Securities
Debt Securities [Member]
Cash and Cash Equivalents [Line Items]
Cash and Cash Equivalents [Line Items]
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents
Cash Equivalents, at Carrying Value [Abstract]
Cash equivalents
Cash Equivalents, at Carrying Value
Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]
Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]
Derivative, by Nature [Axis]
Derivative, by Nature [Axis]
Derivative, Name [Domain]
Derivative, Name [Domain]
Euro
Euro Member Countries, Euro
Canadian Dollar
Canada, Dollars
British pound sterling
United Kingdom, Pounds
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Other Current Assets
Other Current Assets [Member]
Accrued Liabilities
Accrued Liabilities [Member]
Hedging Designation [Axis]
Hedging Designation [Axis]
Hedging Designation [Domain]
Hedging Designation [Domain]
Designated as Hedging Instrument
Designated as Hedging Instrument [Member]
Not Designated as Hedging Instrument [Member]
Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivatives, Fair Value [Line Items]
Aggregate notional amount
Derivative, Notional Amount
Summary of derivatives designated as hedging instruments
Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]
Asset derivatives
Derivative Asset, Fair Value, Gross Asset
Liability derivatives
Derivative Liability, Fair Value, Gross Liability
Segment Reporting [Abstract]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
U.S
UNITED STATES
Europe
Europe [Member]
Germany
GERMANY
Asia
Asia [Member]
Other
Segment Geographical Groups Of Countries Group Other [Member]
Segment geographical groups of countries group other.
Revenue, Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Geographic information
Segments, Geographical Areas [Abstract]
Revenues from unconsolidated joint business
Revenues From Unconsolidated Joint Business
Revenues from unconsolidated joint business.
Other revenues from external customers
Long-lived assets
Long-Lived Assets
Receivables [Abstract]
Accounts Receivable
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]
Quarterly Financial Data (Unaudited)
Schedule of Quarterly Financial Information [Table Text Block]
Summary of assets and liabilities recorded at fair value
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Fair value of venture capital investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Summary of fair and carrying value of debt instruments
Fair Value, by Balance Sheet Grouping [Table Text Block]
Fair value of contingent consideration obligations
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Performance-Vested Restricted Stock Units (PVRSUs)
Performance Vested Restricted Stock Units Activity [Abstract]
Performance vested restricted stock units activity.
Income Statement [Abstract]
Revenues:
Revenues [Abstract]
Unconsolidated joint business
Total revenues
Cost and expenses:
Costs and Expenses [Abstract]
Cost of sales, excluding amortization of acquired intangible assets
Cost of Goods Sold
Research and development
Research and Development Expense (Excluding Acquired in Process Cost)
Selling, general and administrative
Selling, General and Administrative Expense
Collaboration profit sharing
Collaboration profit sharing
Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.
(Gain) loss on fair value remeasurement of contingent consideration
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Restructuring charges
Restructuring Charges
Total cost and expenses
Costs and Expenses
Income from operations
Operating Income (Loss)
Other income (expense), net
Other Nonoperating Income (Expense)
Income before income tax expense and equity in loss of investee, net of tax
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Income tax expense
Equity in loss of investee, net of tax
Income (Loss) from Equity Method Investments
Net income
Net income attributable to noncontrolling interests, net of tax
Net Income (Loss) Attributable to Noncontrolling Interest
Net income attributable to Biogen Idec Inc.
Net income per share:
Earnings Per Share [Abstract]
Weighted-average shares used in calculating:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Basic earnings per share attributable to Biogen Idec Inc.
Weighted Average Number of Shares Outstanding, Basic
Diluted earnings per share attributable to Biogen Idec Inc.
Weighted Average Number of Shares Outstanding, Diluted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative and Other Relationships
Collaborative Arrangement Disclosure [Text Block]
Accounting Policies [Abstract]
Property, plant and equipment estimated useful lives
Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]
Schedule of property plant and equipment useful lives.
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Facility Location [Axis]
Facility Location [Axis]
-- None. No documentation exists for this element. --
Facility Location [Domain]
Facility Location [Domain]
-- None. No documentation exists for this element. --
Cambridge Leases
Cambridge Leases [Member]
Cambridge leases.
Hillerod Denmark Facility
Hillerod Denmark Facility [Member]
Hillerod Denmark Facility.
Eisai
Eisai [Member]
Eisai [Member]
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Depreciation expense
Depreciation
Interest cost capitalization related to construction in progress
Interest Costs Capitalized
Derecognition of construction in progress assets
Derecognition of construction in progress assets
Derecognition of construction in progress assets
Construction cost incurred not yet paid
Remaining Obligation Of Financing Arrangements
Remaining obligation of financing arrangements.
Charges recognized to vacate building
Charges recognized to vacate building
Charges recognized to vacate building
Total cost
Property, Plant and Equipment, Gross
Average estimated useful life
Property, Plant and Equipment, Useful Life
Term of lease
Term Of Lease
Term Of Lease.
Cancellation Period of Lease
Cancellation Period of Lease
The period over which the lease is cancellable.
Assumptions used in valuation of market based stock units
Valuation of Granted Stock Units [Abstract]
Valuation of granted stock units.
Expected dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Range of expected stock price volatility
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Minimum range of risk-free interest rates
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Maximum range of risk-free interest rates
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
60 calendar day average stock price on grant date minimum
Average Stock Price On Grant Date In Dollars Minimum
Average stock price on grant date in dollars minimum.
60 calendar day average stock price on grant date maximum
Average Stock Price On Grant Date In Dollars Maximum
Average stock price on grant date in dollars maximum.
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
GAZYVA [Member]
GAZYVA [Member]
GAZYVA [Member]
RITUXAN
Roche Group - Genentech
Roche Group Genentech Member
Roche group Genentech.
Outside the U.S
Foreign Tax Authority [Member]
Collaborative arrangements and non-collaborative arrangement transactions
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion profit sharing formula
Co Promotion Profit Sharing Formula [Abstract]
Co-promotion profit sharing formula.
Until GAZYVA First Non-CLL FDA Approval
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One
Percentage of co promotion operating profits greater than first fifty million option one.
After First GA101 Threshold Date
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]
Percentage of co promotion operating profits greater than first fifty million option two.
Until First GAZYVA Threshold Date
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One
Percentage of co promotion operating profits greater than first fifty million option two sub option one.
After First Threshold Date and until Second Threshold Date
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two
Percentage of co promotion operating profits greater than first fifty million option two sub option two.
After Second Threshold Date
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three
Percentage of co promotion operating profits greater than first fifty million option two sub option three.
Revenues from unconsolidated joint business
Revenues From Unconsolidated Joint Business [Abstract]
Revenues from unconsolidated joint business.
Biogen Idec's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA
Share Of Co Promotion Profits
Share of co promotion profits.
Reimbursement of our selling and development expenses in the U.S. for RITUXAN
Reimbursement Of Selling And Development Expenses
Reimbursement of selling and development expenses.
Revenue on sales in the rest of world for RITUXAN
Total unconsolidated joint business revenues
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Quoted Prices in Active Markets (Level 1)
Fair Value, Inputs, Level 1 [Member]
Significant Other Observable Inputs (Level 2)
Fair Value, Inputs, Level 2 [Member]
Significant Unobservable Inputs (Level 3)
Fair Value, Inputs, Level 3 [Member]
Fair Value by Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring
Fair Value, Measurements, Recurring [Member]
Fair Value by Asset Class [Axis]
Asset Class [Axis]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain]
Asset Class [Domain]
Corporate debt securities
Corporate Debt Securities [Member]
Government securities
US Treasury and Government [Member]
Mortgage and other asset backed securities
Asset-backed Securities [Member]
Marketable equity securities
Marketable Equity Securities [Member]
Marketable equity securities.
Venture capital investments
Venture Capital Investments [Member]
Venture capital investments.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of assets and liabilities recorded at fair value
Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]
Assets:
Assets, Fair Value Disclosure [Abstract]
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Marketable debt securities
Available-for-sale Securities
Investments
Investments, Fair Value Disclosure
Derivative contracts
Foreign Currency Contract, Asset, Fair Value Disclosure
Plan assets for deferred compensation
Plan Assets For Deferred Compensation Fair Value Disclosure
Fair values as of the balance sheet date of all assets of deferred compensation plans.
Total
Assets, Fair Value Disclosure
Liabilities:
Liabilities, Fair Value Disclosure [Abstract]
Derivative contracts
Foreign Currency Contracts, Liability, Fair Value Disclosure
Contingent consideration obligations
Business Combination, Contingent Consideration, Liability
Total
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Comprehensive Income (Loss) Note
Comprehensive Income (Loss) Note [Text Block]
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Variable Interest Entities [Table]
Schedule of Variable Interest Entities [Table]
Variable Interest Entities [Axis]
Variable Interest Entities [Axis]
Variable Interest Entity, Classification [Domain]
Variable Interest Entity, Classification [Domain]
Neurimmune
Neurimmune [Member]
Neurimmune.
Knopp
KNOPP [Member]
Knopp.
Variable Interest Entity [Line Items]
Variable Interest Entity [Line Items]
Summary of activity related to collaboration
Summary Of Activity Related To Collaboration With Company One [Abstract]
Summary of activity related to collaboration with company one
Biogen Idec's share of expense reflected within our consolidation statements of income
Expense Reflected Within Statements Of Income
Biogen Idec's share of expense reflected within our consolidated statements of income.
Collaboration expense attributed to noncontrolling interests, net of tax
Other Payments To Noncontrolling Interests Net Of Tax
Other payments to noncontrolling interests, net of tax.
Total expense incurred by Biogen Idec
Development Expense Incurred By Collaboration Excluding Upfront And Milestone Payments
Total development expense incurred by collaboration, excluding upfront and milestone payments.
Estimate of additional amounts to be incurred by us in development of the lead compound
Estimate Of Additional Amounts To Be Incurred In Product Development
Estimate of additional amounts to be incurred in product development.
Equity Method Investee, Name [Axis]
Investment, Name [Axis]
Equity Method Investee, Name [Domain]
Investment, Name [Domain]
Samsung Biosimilar Agreement
Samsung Biosimilar Agreement [Member]
Samsung bio-similar agreement.
Term of lease
Future minimum rental commitments
Operating Leases, Future Minimum Payments Due
Additional contingent payment for Biologic License
Additional contingent payment for marketing authorization
Amount paid in cash
Increase to goodwill
Commitments And Contingencies (Textual)
Commitments And Contingencies (Textual) [Abstract]
Commitments And Contingencies.
Lease rent expense which terminates at various dates through 2028
Operating Leases, Rent Expense
Liabilities associated with uncertain tax positions
Liability for Uncertain Tax Positions, Current
Payments to Acquire Equity Method Investments
Payments to Acquire Equity Method Investments
Equity Method Investments
Equity Method Investments
Funding commitments, Approximately
Approximately Funding Commitments In Biotechnology Oriented Venture Capital Funds
Approximately funding commitments in biotechnology oriented venture capital funds.
Accrued expenses
Accrued Expenses On Funding Commitment Related To Clinical Research
Accrued expenses on funding commitment related to clinical research.
Cancellable future commitments
Cancellable Future Commitments
Cancellable future commitments.
Potential future milestone payments commitment, approximately
Potential Future Milestone Payments Commitment To Third Party Approximately
Potential future milestone payments commitment to third party approximately.
Minimum rental commitments under non-cancelable leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of milestone payments based on the attainment of certain sales levels
Schedule of milestone payments based on the attainment of certain sales levels [Table Text Block]
[Table Text Block] for Schedule of milestone payments based on the attainment of certain sales levels [Table]
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Debt Instrument [Axis]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Notes Payable to Fumedica
Notes Payable To Fumedica [Member]
Notes payable.
6.0% Senior Notes due 2013
Senior Notes Six Point Zero Percent Due Twenty Thirteen [Member]
Senior Notes Six Point Zero Percent Due Twenty Thirteen.
6.875% Senior Notes due 2018
Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]
Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.
Debt Instrument
Debt Instrument [Line Items]
Summary of fair and carrying value of debt instruments
Summary of fair and carrying value of debt instruments [Abstract]
Summary of fair and carrying value of debt instruments.
Notes payable, fair value
Notes Payable, Fair Value Disclosure
Credit facility, amount outstanding
Line of Credit Facility, Amount Outstanding
Total fair value
Debt Instrument, Fair Value Disclosure
Gain on Sale of Rights
Gain on Sale of Rights [Text Block]
Gain on Sale of Rights [Text Block]
Components of property, plant and equipment, net
Property, Plant and Equipment [Table Text Block]
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net income to net cash flows from operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization of property, plant and equipment, and intangible assets
Depreciation, Depletion and Amortization
Share-based compensation
Share-based Compensation
Deferred income taxes
Deferred Income Tax Expense (Benefit)
Other
Other Noncash Income (Expense)
Changes in operating assets and liabilities, net:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventory
Increase (Decrease) in Inventories
Other assets
Increase (Decrease) in Other Operating Assets
Accrued expenses and other current liabilities
Increase (Decrease) in Accrued Liabilities
Other liabilities and taxes payable
Increase (Decrease) in Other Operating Liabilities
Other
Increase (Decrease) in Other Operating Assets and Liabilities, Net
Net cash flows provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Proceeds from sales and maturities of marketable securities
Proceeds from Sale and Maturity of Available-for-sale Securities
Purchases of marketable securities
Payments to Acquire Available-for-sale Securities
Acquisition of TYSABRI rights
Acquisitions of businesses and variable interest entities, net of cash acquired
Payments to Acquire Businesses, Net of Cash Acquired
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Other
Payments for (Proceeds from) Other Investing Activities
Net cash flows used in investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Purchase of treasury stock
Proceeds from issuance of stock for share-based compensation arrangements
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options
Excess tax benefit from share-based compensation
Excess Tax Benefit from Share-based Compensation, Financing Activities
Acquisition of noncontrolling interests
Payments For Acquisition Of Noncontrolling Interest
Payments for acquisition of noncontrolling interest.
Repayments of borrowings
Repayments of Debt
Other
Proceeds from (Payments for) Other Financing Activities
Net cash flows used in financing activities
Net Cash Provided by (Used in) Financing Activities
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Effect of exchange rate changes on cash and cash equivalents
Effect of Exchange Rate on Cash and Cash Equivalents
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year
Land
Land
Buildings
Buildings and Improvements, Gross
Leasehold improvements
Leasehold Improvements, Gross
Machinery and equipment
Machinery and Equipment, Gross
Computer software and hardware
Computer software and hardware
Computer software and hardware
Furniture and fixtures
Furniture and Fixtures, Gross
Construction in progress
Construction in Progress, Gross
Total cost
Less: accumulated depreciation
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Total property, plant and equipment, net
Biogen Idec International Neuroscience GmbH
Biogen Idec International Neuroscience Member
Biogen idec international neuroscience.
Contingent Consideration by Type [Axis]
Contingent Consideration by Type [Axis]
Contingent Consideration Type [Domain]
Contingent Consideration Type [Domain]
Other Liabilities Non Current
Other Liabilities Non Current [Member]
Other liabilities non current.
Venture capital investments as percentage of our assets
Venture Capital Investments As Percentage Of Our Assets
Venture capital investments as a percentage of our total assets.
Percentage of venture capital investments to assets
Percentage Of Venture Capital Investments To Assets
Percentage of venture capital investments to assets.
Interest rate on senior notes
Debt Instrument, Interest Rate, Stated Percentage
Contingent consideration obligations
Additions
Discount rate used for net cash outflow projections for fair value measurement
Fair Value Inputs, Discount Rate
Fair value measurements, changes in valuation techniques
Fair Value Measurements, Changes in Valuation Techniques
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]
Income before income taxes (benefit):
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
Domestic
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Foreign
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Income tax expense (benefit):
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal
Current Federal Tax Expense (Benefit)
State
Current State and Local Tax Expense (Benefit)
Foreign
Current Foreign Tax Expense (Benefit)
Total
Current Income Tax Expense (Benefit)
Deferred
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal
Deferred Federal Income Tax Expense (Benefit)
State
Deferred State and Local Income Tax Expense (Benefit)
Foreign
Deferred Foreign Income Tax Expense (Benefit)
Total
Total income tax expense
Other Comprehensive Income Location [Axis]
Other Comprehensive Income Location [Axis]
Other Comprehensive Income Location [Domain]
Other Comprehensive Income Location [Domain]
Other comprehensive income loss before reclassifications [Member]
Other comprehensive income loss before reclassifications [Member]
Other comprehensive income loss before reclassifications [Member]
Equity Components [Axis]
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other income (expense)
Revenues
Net income
Lower range of durations of foreign currency forward contracts
Derivative, Lower Remaining Maturity Range
Higher range of durations of foreign currency forward contracts
Derivative, Higher Remaining Maturity Range
Gain/Loss on fair value of foreign currency forward contracts
Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax
Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.
Expected settlement time for contracts, in months
Maximum Remaining Maturity of Foreign Currency Derivatives
Net gains (losses) of other income (expense) related to foreign currency forward contracts
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
Summary of preferred stock
Summary Of Preferred Stock [Table Text Block]
Summary of preferred stock.
Summary of common stock
Summary Of Common Stock [Table Text Block]
Summary of common stock.
Schedule of Defined Benefit Plans Disclosures [Table]
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Axis]
Defined Benefit Plans and Other Postretirement Benefit Plans [Axis]
Defined Benefit Plans and Other Postretirement Benefit Plans [Domain]
Defined Benefit Plan and Other Postretirement Benefit Plan [Domain]
Savings plan [Member]
Savings Plan [Member]
Savings plan.
Deferred compensation plan [Member]
Deferred Compensation Plan [Member]
Deferred compensation plan.
German plan [Member]
German Plan [Member]
German plan.
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Disclosure [Line Items]
Minimum Qualifying Age For Employee Benefit Plan
Minimum Qualifying Age For Employee Benefit Plan
Minimum qualifying age for employee benefit plan.
Employee Benefit Plans (Textual) [Abstract]
Employee Benefit Plans (Textual) [Abstract]
Employee benefit plans.
Expenses related to savings plan
Defined Contribution Plan, Cost Recognized
Deferred compensation related to Employee Benefit Plan
Deferred Compensation Liability, Classified, Noncurrent
Percentage of minimum investment return
Percentage Of Minimum Investment Return
Percentage of minimum investment return.
Unfunded net pension
Defined Benefit Plan, Funded Status of Plan
Employee Benefit Plan obligations
Defined Benefit Plan, Benefit Obligation
Pension Expense
Pension Expense
Periodic pension cost
Defined Benefit Plan, Net Periodic Benefit Cost
Loss Contingency, Information about Litigation Matters [Abstract]
Litigation
Legal Matters and Contingencies [Text Block]
Stock Option Activity
Stock Option Activity [Abstract]
Stock option activity.
Beginning Balance, Outstanding shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Beginning Balance, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Shares, Granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Weighted Average Exercise Price, Granted
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Shares, Exercised
Weighted Average Exercise Price, Exercised
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Shares, Cancelled
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Weighted Average Exercise Price, Cancelled
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Ending Balance, Outstanding shares
Ending Balance, Weighted Average Exercise Price
Proceeds from Marketable Debt Securities
Proceeds from Marketable Debt Securities [Abstract]
Proceeds from marketable debt securities.
Proceeds from maturities and sales
Realized gains
Available-for-sale Securities, Gross Realized Gains
Realized losses
Available-for-sale Securities, Gross Realized Losses
Debt Disclosure [Abstract]
Indebtedness
Debt Disclosure [Text Block]
Inventory Disclosure [Abstract]
Inventory
Inventory Disclosure [Text Block]
Schedule of Accumulated Other Comprehensive Income (Loss)
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Reclassification out of Accumulated Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
Revenue by product
Revenue from External Customers by Products and Services [Table Text Block]
Geographic information
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
Shares issued under employee stock purchase plan
Shares Issued Under Employee Stock Purchase Plan [Abstract]
Shares issued under employee stock purchase plan.
Shares issued under ESPP
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Cash received under ESPP
Stock Issued During Period, Value, Employee Stock Purchase Plan
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
6.0% Senior notes due 2013
Senior Notes One [Member]
Senior notes one.
6.875% Senior notes due 2018
Senior Notes Two [Member]
Senior notes two.
Note payable to Fumedica
Notes Payable, Other Payables [Member]
Financing arrangements
Financing Arrangements [Member]
Financing arrangements.
Current portion:
Long-term Debt, Current Maturities [Abstract]
Current portion of notes payable
Notes Payable, Current
Current portion of credit facility
Line of Credit, Current
Current portion of notes payable and line of credit
Non-current portion:
Long-term Debt, Excluding Current Maturities [Abstract]
Non-current notes payable
Notes Payable, Noncurrent
Non-current portion of notes payable and other financing arrangements
Financial Instruments
Cash, Cash Equivalents, and Marketable Securities [Text Block]
Components of inventories
Inventory, Net [Abstract]
Raw materials
Inventory, Raw Materials, Net of Reserves
Work in process
Inventory, Work in Process, Net of Reserves
Finished goods
Inventory, Finished Goods, Net of Reserves
Total inventory
Inventory reclassification
Inventory reclassification
Reclassification of the components of inventory.
Inventory, Various Programs, Gross
Inventory, Various Programs, Gross
Gross inventory of various programs which have been capitalized in advance of regulatory approval.
Write-downs on excess, obsolete, unmarketable or other inventory
Inventory Write-down
Analysis of the change in reserves
Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]
Analysis of amount of and change in product revenue reserves.
Total reserves, included in consolidated balance sheets
Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]
Summary of total product revenue reserves included in consolidated balance sheets.
Basic and diluted earnings per share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Components of deferred tax assets and liabilities
Components of Deferred Tax Assets and Liabilities [Abstract]
Tax credits
Deferred Tax Assets, Tax Credit Carryforwards
Inventory, other reserves, and accruals
Deferred Tax Assets, Inventory
Capitalized costs
Deferred Tax Assets Capitalized Costs
Deferred tax assets capitalized costs.
Intangibles, net
Deferred Tax Assets Intangible Net
Deferred tax assets intangible net.
Net operating loss
Deferred Tax Assets, Operating Loss Carryforwards
Share-based compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Other
Deferred Tax Assets, Other
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Total deferred tax assets
Deferred Tax Assets, Net of Valuation Allowance
Purchased intangible assets
Deferred Tax Liabilities, Intangible Assets
Unrealized gain on investments and cumulative translation adjustment
Deferred Tax Liabilities Unrealized Gain On Investments And Cumulative Translation Adjustment
Deferred tax liabilities unrealized gain on investments and cumulative translation adjustment.
Inventory
Deferred Tax Liabilities, Inventory
Depreciation, amortization and other
Deferred Tax Liabilities Depreciation Amortization Other
Deferred tax liabilities depreciation amortization other.
Total deferred tax liabilities
Deferred Tax Liabilities, Net
Schedule of Available-for-sale Securities [Table]
Schedule of Available-for-sale Securities [Table]
Schedule of Available-for-sale Securities [Line Items]
Schedule of Available-for-sale Securities [Line Items]
Financial Instruments (Textual)
Financial Instruments (Textual) [Abstract]
Financial Instruments.
Original maturities of commercial paper and short-term debt securities
Debt Instrument, Maturity Date, Description
Average maturity of marketable securities, months
Average Maturity Of Marketable Securities
Average remaining time to maturity of marketable debt securities, available-for-sale securities.
Impairment charges
Impairment Charges Related To Investments In Privately Held Companies
Impairment charges related to investments in privately held companies.
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
AbbVie
AbbVie Member
AbbVie
Summary of activity related to collaboration with Facet Biotech
Summary Of Activity Related To Collaboration With Company Seven [Abstract]
Summary of activity related to collaboration with company seven.
Total expense incurred by collaboration
Expense Incurred By Collaboration
Total expense incurred by collaboration.
Co-promotion profit sharing formula
Co Promotion Profit Sharing Formula [Table Text Block]
Co-promotion profit sharing formula.
Pretax profit sharing formula
Pretax Profit Sharing Formula [Table Text Block]
Pretax Profit Sharing Formula [Table Text Block]
Revenues from unconsolidated joint business
Revenues From Unconsolidated Joint Business [Table Text Block]
Revenues from unconsolidated joint business.
Summary of activity related to collaboration with Acorda
Summary Of Activity Related To Collaboration With Company Four [Table Text Block]
Summary of activity related to collaboration with company four.
Mechanism for reimbursement, under the amended agreement amounts payable
Reimbursement Under The Amended Agreement Amounts Payable [Table Text Block]
Mechanism for reimbursement, under the amended agreement amounts payable.
Summary of activity related to collaboration with AbbVie Inc.
Summary Of Activity Related To Collaboration With Company Seven [Table Text Block]
Summary of activity related to collaboration with company seven.
Summary of activity related to collaboration with Portola Pharmaceuticals, Inc.
Summary Of Activity Related To Collaboration With Company Five [Table Text Block]
Summary of activity related to collaboration with company five.
Components of inventory [Table]
Components of inventory [Table]
Components of inventory.
TYSABRI
TYSABRI [Member]
Tysabri.
Other
Other products [Member]
Other products
Components of inventory
Components of inventory [Line Items]
Components of inventory.
Total finished goods and work in process
Inventory, Finished Goods and Work in Process, Net of Reserves
Reserves for Discounts and Allowances
Reserves [Text Block]
Represents disclosure of our revenue recognition policies and accounting for related reserves for discounts and allowances. This item also provides analyses of the amount of, and change in, total revenue reserves related to our product sales.
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Common stock, par value
Common Stock, Par or Stated Value Per Share
Treasury stock at cost, shares
Treasury Stock, Shares
Debt Instrument, Interest Rate, Stated Percentage
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Measurements, Recurring
Venture capital investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning of year
Unrealized gains included in earnings
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Included In Earnings
Fair value measurement with unobservable inputs reconciliation recurring basis asset gain included in earnings.
Unrealized losses included in earnings
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Loss Included In Earnings
Fair value measurement with unobservable inputs reconciliation recurring basis asset loss included in earnings.
Purchases
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
Fair value, end of year
Revenue from External Customers by Products and Services [Table]
Revenue from External Customers by Products and Services [Table]
DENMARK
DENMARK
Major Distributor [Axis]
Major Distributor [Axis]
Major Distributor.
Major Distributor [Domain]
Major Distributor [Domain]
Major Distributor.
Distributor One
Distributor One [Member]
Distributor one.
Distributor Two
Distributor Two [Member]
Distributor two.
Revenue from External Customer [Line Items]
Revenue from External Customer [Line Items]
Revenues from unconsolidated joint business in percentage
Revenues In Percentage From Unconsolidated Joint Business
Revenues in percentage from unconsolidated joint business.
Entity wide percentage of revenue from major distributors
Entity Wide Percentage Of Revenue From Major Distributors
Entity wide percentage of revenue from major distributors.
Long-lived assets related to operations in Denmark
Segment Information (Textual) [Abstract]
Segment Information (Textual) [Abstract]
Segment Information.
Number of reportable segment
Number of Reportable Segments
Subsequent Events
Subsequent Events [Text Block]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Spain
SPAIN
Italy
Portugal
PORTUGAL
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable balances on product sales from different countries
Accounts Receivable, Net [Abstract]
Current balance included within accounts receivable, net
Non-current balance included within investments and other assets
Accounts Receivable, Net, Noncurrent
Total
Accounts Receivable, Net
Net accounts receivable balances from product sales in selected European countries
Schedule of Accounts Receivable From Product Sales In Foreign Countries [Table Text Block]
Tabular disclosure of the accounts receivable from product sales in various foreign countries.
Components of inventory
Schedule of Inventory, Current [Table Text Block]
Components of inventory by product
ComponentsOfInventoryByProduct [Table Text Block]
Components of inventory by product
Guarantees [Abstract]
Guarantees
Guarantees [Text Block]
Derivative Instruments
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Acorda
Acorda [Member]
Acorda.
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two
Summary of activity related to collaboration with Acorda
Summary Of Activity Related To Collaboration With Company Four [Abstract]
Summary of activity related to collaboration with Company four.
Total upfront and milestone payments made to Acorda
Upfront And Milestones Payments Made To Collaborative Partner
Upfront and milestones payments made to collaborative partner.
Total cost of sales related to royalties and commercial supply reflected within our consolidated statements of income
Summary of Significant Accounting Policies
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Segment Information
Segment Reporting Disclosure [Text Block]
Summary of Indebtedness
Schedule of Debt [Table Text Block]
Total debt maturities
Schedule of Maturities of Long-term Debt [Table Text Block]
Fair value, beginning of period
Payments
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fair value, end of period
Common Class B
Common Class B [Member]
Variable Interest Entities by Classification of Entity [Axis]
Investment in Variable Interest Entities (Textual)
Investment in Variable Interest Entities (Textual) [Abstract]
Investment in Variable Interest Entities.
Percentage of operations of joint venture investments on financial statements
Percentage Of Operations Of Joint Venture Investments Reflected In Consolidated Financial Statements
Percentage of operations from joint-venture investments reflected in the consolidated financial statements.
Percentage of net income (loss) attributable to noncontrolling interests
Net Income Loss Attributable To Noncontrolling Interest Percentage
Net income loss attributable to noncontrolling interest percentage.
Total upfront and reimbursement payment made to collaborative partner
Upfront And Reimbursement Payment Made To Collaborative Partner
Total upfront and reimbursement payment made to collaborative partner.
Purchase of common shares in variable interest entities
Purchase Of Common Shares In Variable Interest Entities
Purchase of common shares in variable interest entities.
Purchase consideration for variable interest entities
Purchase Consideration For Variable Interest Entities
Amount of cash paid to acquire stock of the entity.
Percentage of funding for R&D cost required in support of the collaboration agreement
Research And Development Cost In Support Of Collaboration Agreement
Research and development cost in support of the collaboration agreement.
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement
Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement
Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.
Earnings per Share
Earnings Per Share [Text Block]
Statement of Comprehensive Income [Abstract]
Reclassification adjustment on securities available for sale
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax
Tax effect on net unrealized gains (losses) recognized on securities available for sale
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax
Reclassification adjustment on foreign currency forward contracts
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
Tax effect of net unrealized gains (losses) recognized on foreign currency forward contracts
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
Tax effect of net unrealized gains (losses) recognized on pension benefit obligation
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax
Distributor One
Distributor Two
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Domain]
Building
Building [Member]
Furniture and Fixtures
Furniture and Fixtures [Member]
Machinery and Equipment
Machinery and Equipment [Member]
Computer Equipment
Computer Equipment [Member]
Property, plant and equipment, useful life
Percentage receivables of wholesale distributor accounted in consolidated receivables
Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables
Percentage receivables of wholesale distributor accounted in consolidated receivables.
Business (Textual)
Business (Textual) [Abstract]
Business.
Interest in subsidiary (less than given percentage)
Interest In Subsidiary
Interest in subsidiary.
Payment terms of accounts receivable arising from product sales
Payment Terms Of Accounts Receivable
Payment terms of accounts receivable.
Estimated useful lives of leasehold improvements
Estimated Useful Lives Of Leasehold Improvements
Estimated useful lives of leasehold improvements.
Purchase price of common stock under ESPP
Purchase Price Of Common Stock Under ESPP
Purchase Price Of Common Stock Under ESPP.
Percentage of market value per share of common stock
Percentage Of Market Value Per Share Of Common Stock
Percentage of market value per share of common stock.
Compensation expense over purchase period
Compensation Expense Over Purchase Period
Compensation expense over purchase period.
Discount rate recognized in compensation expense
Discount Rate Recognized In Compensation Expense
Discount rate recognized in compensation expense.
Advertising costs
Advertising Expense
Minimum rental commitments under non-cancelable leases
Minimum Rental Commitments Under Noncancellable Leases [Abstract]
Minimum rental commitments under noncancellable leases.
Minimum lease payments, 2014
Operating Leases, Future Minimum Payments Due, Next Twelve Months
Minimum lease payments, 2015
Operating Leases, Future Minimum Payments, Due in Two Years
Minimum lease payments, 2016
Operating Leases, Future Minimum Payments, Due in Three Years
Minimum lease payments, 2017
Operating Leases, Future Minimum Payments, Due in Four Years
Minimum lease payments, 2018
Operating Leases, Future Minimum Payments, Due in Five Years
Minimum lease payments, Thereafter
Operating Leases, Future Minimum Payments, Due Thereafter
Minimum lease payments, Total
Less: income from subleases, 2014
Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months
Less: income from subleases, 2015
Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years
Less: income from subleases, 2016
Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years
Less: income from subleases, 2017
Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years
Less: income from subleases, 2018
Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years
Less: income from subleases, Thereafter
Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter
Less: income from subleases, Total
Future Minimum Sublease Rentals, Sale Leaseback Transactions
Net minimum lease payments, 2014
Net Minimum Lease Payments With In One Year
Net minimum lease payments with in one year.
Net minimum lease payments, 2015
Net Minimum Lease Payments With In Two Year
Net minimum lease payments with in two year.
Net minimum lease payments, 2016
Net Minimum Lease Payments With In Three Year
Net minimum lease payments with in three year.
Net minimum lease payments, 2017
Net Minimum Lease Payments With In Four Year
Net minimum lease payments with in four year.
Net minimum lease payments, 2018
Net Minimum Lease Payments With In Five Year
Net minimum lease payments with in five year.
Net minimum lease payments, Thereafter
Net Minimum Lease Payments Thereafter
Net minimum lease payments thereafter.
Net minimum lease payments, Total
Net Minimum Lease Payments
Net minimum lease payments total.
Quarterly Financial Data (Unaudited)
Quarterly Financial Information [Text Block]
Business Overview
Business Overview [Policy Text Block]
Describes an overview of the company and its operations.
Consolidation
Consolidation, Policy [Policy Text Block]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Fair Value Measurements
Fair Value of Financial Instruments, Policy [Policy Text Block]
Cash and Cash Equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Accounts Receivable
Receivables, Policy [Policy Text Block]
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Marketable Securities and Other Investments
Investment, Policy [Policy Text Block]
Equity Method of Accounting
Equity Method Investments, Policy [Policy Text Block]
Inventory
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment
Property, Plant and Equipment, Policy [Policy Text Block]
Intangible Assets
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Acquired In-process Research and Development (IPR&D)
In Process Research and Development, Policy [Policy Text Block]
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Impairment of Long-Lived Assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Contingent Consideration
Business Combinations Policy [Policy Text Block]
Derivative Instruments and Hedging Activities
Derivatives, Policy [Policy Text Block]
Translation of Foreign Currencies
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Royalty Cost of Sales
Royalty Cost of Sales [Policy Text Block]
Royalty Cost of Sales [Policy Text Block]
Accounting for Share-Based Compensation
Compensation Related Costs, Policy [Policy Text Block]
Research and Development Expenses
Research, Development, and Computer Software, Policy [Policy Text Block]
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses, Policy [Policy Text Block]
Income Taxes
Income Tax, Policy [Policy Text Block]
Contingencies
Commitments and Contingencies, Policy [Policy Text Block]
Restructuring Charges
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]
Earnings per Share
Earnings Per Share, Policy [Policy Text Block]
New Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Reconciliation between the U.S. federal statutory tax rate and effective tax rate
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory rate
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
State taxes
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Taxes on foreign earnings
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Credits and net operating loss utilization
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Purchased intangible assets
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent
Manufacturing deduction
Effective income tax rate reconciliation manufacturing deduction
Effective income tax rate reconciliation manufacturing deduction
Permanent items
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Contingent consideration
Effective Income Tax Rate Reconciliation Contingent Consideration
Effective income tax rate reconciliation contingent consideration.
Other
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Effective tax rate
Effective Income Tax Rate Reconciliation, Percent
Tax benefit and cash received from stock option
Tax Benefit And Cash Received From Stock Option [Abstract]
Tax benefit and cash received from stock option.
Tax benefit realized for stock options
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options
Cash received from the exercise of stock options
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options
Cash Paid During the Year
Supplemental Cash Flow Information [Abstract]
Interest
Interest Paid, Net
Income taxes
Income Taxes Paid, Net
Other Income (Expense), Net
Interest Income (Expense), Net [Abstract]
Interest income
Investment Income, Interest
Interest expense
Interest Expense
Impairment of investments
Other than Temporary Impairment Losses, Investments
Gain (loss) on sales of investments, net
Gain (Loss) on Sale of Investments
Foreign exchange gains (losses), net
Foreign Currency Transaction Gain (Loss), before Tax
Other, net
Other Income Expense Net
The amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement.
Total other income (expense), net
Accrued Expenses and Other
Accrued Liabilities, Current [Abstract]
Employee compensation and benefits
Employee-related Liabilities, Current
Revenue-related rebates
Revenue Related Rebates
This element represents the accrued rebates at the balance sheet date.
Deferred revenue
Royalties and licensing fees
Accrued Royalties, Current
Clinical development expenses
Clinical Development Expenses
Carrying amount as of the balance sheet date for expenses incurred related to clinical development activities due within one year.
Current portion of contingent consideration obligations
Current Portion Of Contingent Consideration Obligations
Current portion of contingent consideration obligations.
Construction in progress accrual
Construction in progress accrual
Construction in progress accrual
Collaboration expenses
Collaboration Expenses
Carrying amount as of the balance sheet date of payments due to collaborations excluding unconsolidated joint business.
Other
Other Accrued Expenses And Other
Carrying amount as of the balance sheet date of other accrued expenses and other, excluding amounts separately identified within this table.
Total accrued expenses and other
Other Consolidated Financial Statement Detail
Additional Financial Information Disclosure [Text Block]
Portola Pharmaceuticals
Summary of activity related to collaboration with Portola Pharmaceuticals, Inc.
Summary Of Activity Related To Collaboration With Company Five [Abstract]
Summary of activity related to collaboration with Company Five.
Property, Plant and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Stock options and employee stock purchase plan
Stock options and employee stock purchase plan [Member]
Stock options and employee stock purchase plan.
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Basic and diluted earnings per share
Basic And Diluted Earnings Per Share [Abstract]
Basic and diluted earnings per share.
Numerator:
Numerator [Abstract]
Numerator.
Adjustment for net income allocable to preferred stock
Preferred Stock Dividends and Other Adjustments
Net income used in calculating basic and diluted earnings per share
Net Income (Loss) Available to Common Stockholders, Basic
Denominator:
Denominator [Abstract]
Denominator.
Weighted average number of common shares outstanding
Effect of dilutive securities:
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]
Stock options and employee stock purchase plan
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Dilutive potential common shares
Weighted Average Number Diluted Shares Outstanding Adjustment
Shares used in calculating diluted earnings per share
Earnings per share (Textual)
Earnings Per Share (Textual) [Abstract]
Earnings per share.
Repurchase of common stock
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation
Cash settled performance shares
Cash Settled Performance Shares [Abstract]
Cash settled performance shares.
Foreign currency forward contracts that were entered into to hedge forecasted revenue
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]
Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income
Derivative Instruments, Gain (Loss) [Table Text Block]
Summary of the fair value for our outstanding derivatives
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]
Supplementary cash flow information
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
Other income (expense), net
Schedule of Other Nonoperating Income (Expense) [Table Text Block]
Accrued expenses and other
Schedule of Accrued Liabilities [Table Text Block]
Accounts Receivable (Textual)
Minimum term for accounts receivable
Minimum Term For Accounts Receivable
Minimum term for accounts receivable.
Maximum term for accounts receivable
Maximum Term For Accounts Receivable
Maximum term for accounts receivable.
Accounts receivable outstanding for greater than one year
Accounts Receivable Outstanding For Greater Than One Year
Amounts due from customers, greater than one year outstanding for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.
Reimbursement Limit Stated In Resolution
Loss contingency accrual
Loss Contingency Accrual
Cumulative deferred revenue on sales
Deferred Revenue
Amount of revenue deferred during the period
Deferred Revenue, Additions
Reconciliation of the beginning and ending of unrecognized tax benefits
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]
Balance at January 1
Unrecognized Tax Benefits
Additions based on tax positions related to the current period
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Additions for tax positions of prior periods
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Reductions for tax positions of prior periods
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Statute expirations
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Settlements
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Balance at December 31
Corporate debt securities Current
Corporate Debt Securities Current [Member]
Corporate debt securities Current.
Corporate debt securities Non-current
Corporate Debt Securities Non Current [Member]
Corporate Debt Securities Non Current.
Government securities Current
Government Securities Current [Member]
Government securities Current.
Government securities Non-current
Government Securities Non-current [Member]
Government Securities Non Current.
Mortgage and other asset backed securities Current
Mortgage And Other Asset Backed Securities Current [Member]
Mortgage and other asset backed securities Current.
Mortgage and other asset backed securities Non-current
Mortgage And Other Asset Backed Securities Non Current [Member]
Mortgage And Other Asset Backed Securities Non Current.
Marketable Debt and Equity Securities
Available-for-sale Securities [Abstract]
Fair Value
Fair Value
Available-for-sale Securities, Equity Securities, Noncurrent
Gross Unrealized Gains
Available-for-sale Securities, Gross Unrealized Gain
Gross Unrealized Losses
Available-for-sale Securities, Gross Unrealized Loss
Amortized Cost
Available-for-sale Securities, Amortized Cost Basis
Total debt maturities
Long-term Debt, Fiscal Year Maturity [Abstract]
2014
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
2015
Long-term Debt, Maturities, Repayments of Principal in Year Two
2016
Long-term Debt, Maturities, Repayments of Principal in Year Three
2017
Long-term Debt, Maturities, Repayments of Principal in Year Four
2018
Long-term Debt, Maturities, Repayments of Principal in Year Five
2019 and thereafter
Long-term Debt, Maturities, Repayments of Principal after Year Five
Total
Acquisitions
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
Net income attributable to Biogen Idec Inc.
Other comprehensive income:
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Unrealized gains (losses) recognized during the period, net of tax of $6,394, $2,940 and $133
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax
Less: reclassification adjustment for (gains) losses included in net income, net of tax of $5,576, $486 and $7,155
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
Unrealized gains (losses) on securities available for sale, net of tax of $818, $2,454 and $7,288
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Unrealized gains (losses) recognized during the period, net of tax of $1,721, $1,396 and $3,647
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax
Less: reclassification adjustment for (gains) losses included in net income, net of tax of $533, $3,360 and $1,268
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $1,187, $4,756 and $4,915
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
Unrealized gains (losses) on pension benefit obligation
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax
Currency translation adjustment
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Total other comprehensive income (loss), net of tax
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Comprehensive income attributable to Biogen Idec Inc.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income attributable to noncontrolling interests, net of tax
Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Equity Components [Axis]
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Translation Adjustment [Member]
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax beginning balance
Other comprehensive income (loss), before reclassifications
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Amounts reclassified from accumulated other comprehensive income (loss)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Net current period other comprehensive income (loss)
Accumulated other comprehensive income (loss), net of tax ending balance
AVONEX
TYSABRI
Other products
Statement, Business Segments [Axis]
Segments [Axis]
Segment [Domain]
Segments [Domain]
Rest of world
Rest Of World [Member]
Rest of world.
Revenue by product
Sales Revenue, Goods, Net [Abstract]
Equity
Stockholders' Equity Note Disclosure [Text Block]
Intangible assets
Intangible Assets Excluding Goodwill [Table Text Block]
Intangible assets excluding goodwill.
Estimated future amortization of intangible assets
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Summary of roll forward of the changes in goodwill
Schedule of Goodwill [Table Text Block]
Summary of Contractual Maturities: Available-for-Sale Securities
Available-for-sale Securities, Debt Maturities [Abstract]
Due in one year or less, Estimated Fair Value
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value
Due in one year or less, Amortized Cost
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis
Due after one year through five years, Estimated Fair Value
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value
Due after one year through five years, Amortized Cost
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis
Due after five years, Estimated Fair Value
Available For Sale Securities Debt Maturities After Five Years Fair Value
This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.
Due after five years, Amortized Cost
Available For Sale Securities Debt Maturities After Five Years Amortized Cost
This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.
Total available-for-sale securities, Fair Value
Total available-for-sale securities, Amortized Cost
Available-for-sale Securities, Debt Maturities, Amortized Cost Basis
Share-based Payments
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Royalty And Net Revenue Share Rates By Territory [Axis]
Royalty And Net Revenue Share Rates By Territory [Axis]
Royalty and net revenue share rates by territory.
Royalty And Net Revenue Share Rates By Territory [Domain]
Royalty And Net Revenue Share Rates By Territory [Domain]
Royalty and net revenue share rates by territory.
Sobi rate to Biogen on net sales in the Sobi Territory [Member]
Sobi Rate To Biogen On Net Sales In The Sobi Territory [Member]
Sobi rate to Biogen on net sales in the sobi territory.
Biogen rate to sobi on net sales in the Biogen North America Territory [Member]
Biogen Rate To Sobi On Net Sales In The Biogen North America Territory [Member]
Biogen rate to sobi on net sales in the Biogen North America territory.
Biogen rate to sobi on net sales in the Biogen direct Territory [Member]
Biogen Rate To Sobi On Net Sales In The Biogen Direct Territory [Member]
Biogen rate to sobi on net sales in the Biogen direct Territory.
Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member]
Biogen Rate To Sobi On Net Revenue From The Biogen Distributor Territory Member
Biogen rate to Sobi on net revenue(1) from the Biogen distributor territory(2).
Sobi Territory [Member]
Sobi Territory [Member]
Sobi territory.
Mechanism for reimbursement, under the amended agreement amounts payable
Reimbursement Under The Amended Agreement Amounts Payable [Abstract]
Mechanism for reimbursement, under the amended agreement amounts payable.
Reimbursement, under the amended agreement, Method
Reimbursement Under The Amended Agreement Method
Reimbursement, under the amended agreement, method.
Rate prior to first commercial sale in the territory
Rate Prior To First Commercial Sale
Rate prior to first commercial sale.
Base rate following first commercial sale in the territory
Base Rate After First Commercial Sale
Base rate after first commercial sale.
Rate during the reimbursement period
Rate During Reimbursement Period
Rate during the reimbursement period.
Principal amount of senior notes
Debt Instrument, Face Amount
Redemption percentage par value of senior notes
Percentage Par Value Of Senior Notes
Percentage par value of senior notes.
Percentage of redemption of notes
Percentage Of Redemption Of Notes
Percentage of redemption of notes.
Increased carrying amount of interest rate swap
Increased Carrying Amount Of Senior Notes
Increased carrying amount of senior notes.
Interest to be amortized on debt
Debt Instrument Unamortized Interest On Debt
Debt instrument unamortized interest on debt.
Repayments of borrowings
Notes payable and other financing arrangements
Present value of notes payable
Present Value Of Notes Payable
Present value of notes payable.
Senior unsecured revolving credit facility maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Remaining obligation of financing arrangements
Debt Instrument, Payment Terms
Debt Instrument, Payment Terms
Time-vested restricted stock units
Restricted Stock Units Activity [Abstract]
Restricted stock units activity.
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]
Research and development
Research and Development Expense [Member]
Selling, general and administrative
Selling, General and Administrative Expenses [Member]
Restructuring Charges
Restructuring Charges [Member]
Total share-based compensation expense, net of tax
Parent [Member]
Share-based Compensation Expense included in consolidated statements of income
Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]
Income tax effect
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense
Summary Of Activity Related To Collaboration With Knopp
Summary Of Activity Related To Collaboration With Company Three [Table Text Block]
Summary of activity related to collaboration with company three.
Summary Of Activity Related To Collaboration With Neurimmune
Summary Of Activity Related To Collaboration With Company One [Table Text Block]
Summary of activity related to collaboration with company one.
Summary Of Activity Related To Collaboration With Neurimmune Along With Estimate Of Additional Future Development
Summary Of Activity Related To Collaboration With Company One Along With Estimate Of Additional Future Development [Table Text Block]
Summary of activity related to collaboration with Company one along with an estimate of additional future development.
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward, Name [Domain]
General Business
General Business Tax Credit Carryforward [Member]
Research
Research Tax Credit Carryforward [Member]
Income Tax Authority [Axis]
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Income Tax Authority [Domain]
Domestic Country
Domestic Tax Authority [Member]
State and Local Jurisdiction
State and Local Jurisdiction [Member]
Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward [Line Items]
Total deferred charges and prepaid taxes
Total deferred charges and prepaid taxes
Total deferred charges and prepaid taxes
Deferred tax liability recognized
Deferred tax liability recognized
Deferred tax liability recognized
Operating Loss Carryforwards
Operating Loss Carryforwards
Tax Credit Carryforward, Amount
Tax Credit Carryforward, Amount
Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries
Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries
Estimated tax liability on undistributed earnings of foreign subsidiaries.
Net benefit for a previously unrecognized position
Net benefit for a previously unrecognized position
Net benefit for a previously unrecognized position
Expense for non-income based state taxes
Expense for non-income based state taxes
Expense for non-income based state taxes
Proposed Disallowance By Tax Authorities For Payment For Services
Proposed Disallowance By Tax Authorities For Payment For Services
Proposed disallowance by tax authorities for payment for services.
Income Taxes (Textual)
Income Taxes (Textual) [Abstract]
Income Taxes.
Undistributed Foreign Earnings Of Non Us Subsidiaries
Undistributed Earnings of Foreign Subsidiaries
Unrecognized tax benefit
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Net Interest Expense Benefit
Net Interest Expense Benefit
Net interest expense/benefit.
Unrecognized Tax Benefits, Interest on Income Taxes Accrued
Unrecognized Tax Benefits, Interest on Income Taxes Accrued
Notice of Assessment of corporate excise tax including penalties and interest
Assessment Of Tax Including Penalties And Interest
The amount associated with the Notice of Assessment of corporate tax including penalties and interest, subject to litigation.
Tax Adjustments, Settlements, and Unusual Provisions
Tax Adjustments, Settlements, and Unusual Provisions
Tax Adjustments And Settlements Interest
Tax Adjustments And Settlements Interest
Tax adjustments and settlements interest.
Cash and cash equivalents
Cash and Cash Equivalents [Member]
Additional Products [Axis]
Additional Products [Axis]
Additional products.
Additional Products [Domain]
Additional Products [Domain]
Additional products.
New Anti-CD20
New Anti Cd20 [Member]
New Anti-CD20.
Third Party Anti CD-20
Third Party Anti CD Twenty [Member]
Third Party Anti CD 20.
Ocrelizumab
Ocrelizumab [Member]
Ocrelizumab.
Genentech
Elan
Elan [Member]
Elan.
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum [Member]
Swedish orphan biovitrum.
Proteostasis Therapeutics
Proteostasis Therapeutics [Member]
Proteostasis Therapeutics [Member]
Other research and discovery
Other research and discovery [Member]
Other research and discovery [Member]
Royalties Terms Of Collaboration Agreement
Royalties Terms Of Collaboration Agreement
Royalties terms of collaboration agreement.
Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World
Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World
Royalty period for substantially all of the remaining royalty-bearing sales of RITUXAN in the rest of world.
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three
Collaborative and Other Relationships (Textual)
Collaborations (Textual) [Abstract]
Collaborations.
Percentage of royalties as per collaboration
Percentage Of Royalties As Per Collaboration
Percentage of royalties as per collaboration.
Period of collaboration agreement
Period Of Collaboration Agreement
Period of collaboration agreement.
Percentage of future development and commercialization expenses payable related to GAZYVA
Percentage Of Development And Commercialization Expenses Payable Related
Percentage of development and commercialization expenses payable related.
Future royalties percentage to be received on sale of ocrelizumab
Future Royalties Percentage To Be Received On Sale Of Product
Future royalties percentage to be received on sale of product.
Percentage of Co promotion Operating Profits first fifty million
Percentage Of Co Promotion Operating Profits First Fifty Million
Percentage of co promotion operating profits first fifty million.
Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment
Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment
Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one
Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One
Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one
Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One
Threshold of gross sales to be achieved in any twelve consecutive months under option one.
Sales Trigger Gross Sales Threshold
Sales Trigger Gross Sales Threshold
Sales trigger gross sales threshold.
Future percentage of co-promotion operating profits
Future percentage of co-promotion operating profits
Future percentage of co-promotion operating profits
Percentage Of Co Promotion Operating Losses
Percentage Of Co Promotion Operating Losses
Percentage Of Co Promotion Operating Losses
Estimates of compensatory damages and interest
Estimates Of Compensatory Damages And Interest
Estimates of compensatory damages and interest.
Compensatory damages and interest
Percentage of share of Co promotion profits exceeding $50 million
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million
Percentage of co promotion operating profits greater than first fifty million.
Reimbursements of research and developments expense from Elan
Reimbursements Of Research And Developments Expense From Collaboration Partner
Reimbursements of research and developments expense from collaboration partner.
Reimbursements of selling general and administrative expenses from Elan
Reimbursements Of Selling General And Administrative Expenses From Collaboration Partner
Reimbursements of selling general and administrative expenses from collaboration partner.
Amount reflected in collaboration profit sharing line for collaboration
Amount Reflected In Collaboration Profit Sharing Line For Collaboration
Amount reflected in collaboration profit sharing line for collaboration.
Total milestone payments
Milestones Payments Made To Collaborative Partners
Milestones payments made to collaborative partners.
Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones
Expected Additional Milestone Payments On Successful Achievement Of Regulatory And Commercial Sales Milestones
Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones.
Expected additional milestone payments when certain sales threshold is met
Expected Additional Milestone Payments When Meeting Certain Sales Threshold
Expected additional milestone payments when meeting certain sales threshold.
Foreign sales required to trigger milestone
Foreign Sales Required To Trigger Milestone
Foreign sales required to trigger milestone.
Stock acquired in acquisition
Business Acquisition, Percentage of Voting Interests Acquired
Consideration per product
Consideration Per Product Developed
Consideration per product developed.
Percentage of reimbursement expenses
Percentage Of Reimbursement Expenses
Percentage of reimbursement expenses.
Percentage of development reimbursement expenses
Percentage Of Development Reimbursement Expenses
Percentage of development reimbursement expenses.
Reimbursement cost achieving period
Reimbursement Cost Achieving Period
Reimbursement cost achieving period.
Time period for paying remaining balance due
Time Period For Paying Remaining Balance Due
Time period for paying remaining balance due.
Term for revocation option right
Period For Granting Of Approval By Approving Authority
Period for granting of approval by approving authority.
Estimated additional payments upon achievement of development and commercial milestones.
Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones
Estimated additional payments upon achievement of development and commercial milestones.
Amount paid to purchase Portola equity
Amount Paid To Purchase Of Equity Of Collaborative Partner
Amount paid to purchase Portola equity.
Gain Loss From Sale Of Strategic Equity Investments
Term of collaboration agreement
Term of collaboration agreement
Term of collaboration agreement
Total upfront and milestone payments made to collaborative partner
Upfront And Milestone Payments Made To Collaborative Partner
Total upfront and milestone payments made to collaborative partner.
Prepaid research and discovery services
Prepaid Expense and Other Assets
License Fee
License Fee
License Fee
Expected License Fee And Regulatory Milestone Payments
Expected License Fee And Regulatory Milestone Payments
Expected license fee and regulatory milestone payments.
Additional milestone payments for product candidate using a different modality
Additional milestone payments for product candidate using a different modality
Additional milestone payments for product candidate using a different modality
Investments By Third Party In Joint Venture As Per Agreement.
Investments By Third Party In Joint Venture As Per Agreement.
Investments by third party in joint venture as per agreement
Other Assets, Noncurrent
Joint Venture Owner Ship Percentage By Third Party.
Joint Venture Owner Ship Percentage By Third Party.
Joint venture owner ship percentage by third party.
Equity Method Investment Ownership Percentage Maximum
Equity Method Investment Ownership Percentage Maximum
Equity method investment ownership percentage maximum.
Income (Loss) from Equity Method Investments